Another study has demonstrated that pristimerin improves intracellular ROS levels through both stimulating excessive generation of superoxide in mitochondria and abrogating intracellular ROS scavenger GSH level in glioma cells, consequently activates JNK (54). This evidence concerns the gene MAPK8 and glioma.